Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin

5 lipca 2017 zaktualizowane przez: Pfizer

A 12-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Once Daily Pf-06291874 Administration In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin

The purpose of this study is to determine whether PF-06291874 is effective in the treatment T2DM

Przegląd badań

Status

Zakończony

Warunki

Interwencja / Leczenie

Szczegółowy opis

This will be a randomized, double blind, stratified, placebo controlled, parallel group study conducted in T2DM subjects receiving background metformin therapy. Subjects will complete screening procedures to determine eligibility, followed by an 8 week metformin stabilization period prior to randomization. In addition, subjects taking other OADs, in combination with metformin, will undergo a washout during this period, in which non metformin OAD medications will be temporarily discontinued for the duration of the trial. Following confirmation of study eligibility criteria at randomization, subjects will be stratified into 2 groups based on the use of concomitant statin therapy. Each stratum will be randomized across treatment groups, such that the number of subjects taking concomitant statin therapy and those not taking statin therapy will be approximately balanced across treatment groups.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

206

Faza

  • Faza 2

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

  • Kanada
    • Ontario
      • Brampton, Ontario, Kanada, L6T 0G1
        • Aggarwal and Associates Limited
      • Thornhill, Ontario, Kanada, L4J 8L7
        • LMC Clinical Research Inc. (Thornhill)
      • Toronto, Ontario, Kanada, M4G 3E8
        • LMC Clinical Research Inc. (Bayview)
      • Toronto, Ontario, Kanada, M9W 4L6
        • Manna Research
    • Quebec
      • Lévis, Quebec, Kanada, G6W 0M6
        • Manna Research Inc.
      • Mirabel, Quebec, Kanada, J7J 2K8
        • Omnispec Clinical Research, Inc.
  • Stany Zjednoczone
    • California
      • Anaheim, California, Stany Zjednoczone, 92801
        • Anaheim Clinical Trials, LLC
      • Los Angeles, California, Stany Zjednoczone, 90057
        • National Research Institute
      • Orange, California, Stany Zjednoczone, 92868
        • NRC Research Institute
      • Roseville, California, Stany Zjednoczone, 95661
        • Sierra Clinical Research
      • Spring Valley, California, Stany Zjednoczone, 91978
        • Encompass Clinical Research
      • Upland, California, Stany Zjednoczone, 91786
        • Empire Clinical Research
      • Walnut Creek, California, Stany Zjednoczone, 94598
        • Diablo Clinical Research, Inc
    • Florida
      • Coral Gables, Florida, Stany Zjednoczone, 33134
        • Clinical Research of South Florida
      • DeLand, Florida, Stany Zjednoczone, 32720
        • Avail Clinical Research, LLC
      • Miami, Florida, Stany Zjednoczone, 33135
        • Suncoast Research Group, LLC
      • South Miami, Florida, Stany Zjednoczone, 33143
        • QPS-MRA, LLC (Miami research Associates)
      • West Palm Beach, Florida, Stany Zjednoczone, 33409
        • Palm Beach Research Center
    • Georgia
      • Sandy Springs, Georgia, Stany Zjednoczone, 30328
        • WR-Mount Vernon Clinical Research, LLC
    • Hawaii
      • Honolulu, Hawaii, Stany Zjednoczone, 96814
        • East-West Medical Research Institute
    • Indiana
      • Indianapolis, Indiana, Stany Zjednoczone, 46260
        • Midwest Institute for Clinical Research
    • Louisiana
      • Metairie, Louisiana, Stany Zjednoczone, 70006
        • Crescent City Clinical Research Center, LLC
    • Missouri
      • Saint Louis, Missouri, Stany Zjednoczone, 63141
        • St. Louis Clinical Trials, LC
    • Nevada
      • Las Vegas, Nevada, Stany Zjednoczone, 89120
        • ALAS Science Clinical Research
    • New Jersey
      • Berlin, New Jersey, Stany Zjednoczone, 08009
        • Comprehensive Clinical Research
      • Eatontown, New Jersey, Stany Zjednoczone, 07724
        • Clinilabs Inc.
      • Marlton, New Jersey, Stany Zjednoczone, 08053
        • Pharmaceutical Research Associates, Inc.
      • Trenton, New Jersey, Stany Zjednoczone, 08611
        • TLB Research
    • North Carolina
      • Asheboro, North Carolina, Stany Zjednoczone, 27203
        • Randolph Medical Associates
      • High Point, North Carolina, Stany Zjednoczone, 27265
        • High Point Clinical Trials Center, LLC
    • North Dakota
      • Fargo, North Dakota, Stany Zjednoczone, 58103
        • Lillestol Research, LLC
    • Ohio
      • Columbus, Ohio, Stany Zjednoczone, 43213
        • Aventiv Research
    • Texas
      • Houston, Texas, Stany Zjednoczone, 77081
        • Texas Center for Drug Development, Inc.
      • Houston, Texas, Stany Zjednoczone, 77074
        • Juno Research, LLC
      • Katy, Texas, Stany Zjednoczone, 77450
        • Juno Research, LLC
      • San Antonio, Texas, Stany Zjednoczone, 78229
        • Clinical Trials of Texas, Inc.
      • Schertz, Texas, Stany Zjednoczone, 78154
        • Northeast Clinical Research of San Antonio, LLC
    • Virginia
      • Richmond, Virginia, Stany Zjednoczone, 23294
        • National Clinical Research - Richmond, Inc.

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 70 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  1. Males or non-childbearing potential females between the ages of 18 (or the minimum country specific age of consent if >18) and 70 years, inclusive, at the screening visit (V1) with the diagnosis of T2DM;Female subjects who are not of childbearing potential
  2. Subjects who have been on a stable dose of metformin either alone or in combination with one additional acceptable OAD
  3. HbA1c at the Screen Visit (V1), as assessed by study specific central laboratory, is 7-11% if on metformin monotherapy; is 6.5-9.5% if on dual combination therapy (metformin plus 1)

Exclusion Criteria:

  1. Diagnosis of type 1 diabetes mellitus or secondary forms of diabetes;
  2. Fasting plasma glucose levels >270 mg/dL (15.0 mmol/L) at the screening and run in visit, (as assessed by study specific central laboratory) confirmed by a single repeat, if deemed necessary
  3. History of myocardial infarction, unstable angina, arterial revascularization, stroke, New York Heart Association Functional Class III IV heart failure, or transient ischemic attack within 6 months of screening;
  4. Any medical condition possibly affecting study drug absorption (eg, gastrectomy or any area of intestinal resection, active inflammatory bowel disease or pancreatic insufficiency
  5. Subjects with a creatinine clearance <60 mL/min as determined by the Cockcroft Gault equation (listed below) using serum creatinine measured at screening, confirmed via a single repeat, if deemed necessary
  6. Subject with a positive result for hepatitis B surface antigen (HBsAg), hepatitis B core antibodies (HBc Ab) or hepatitis C virus (HCV) antibodies
  7. Screening seated systolic blood pressure >160 mm Hg and/or diastolic blood pressure >105 mm Hg after at least a 5 minute rest. Blood pressure determined as the mean of triplicate measurements collected with approximately 2 minutes of rest between measurements
  8. Screening supine 12 lead ECG demonstrating a corrected QT (QTc) >470 msec; or a QRS interval >120 msec. If QTc exceeds 470 msec or QRS exceeds 120 msec, the ECG may be repeated 2 more times with an interval of 2-4 minutes between each measurement and the mean of the 3 values used to determine the subject's eligibility
  9. Subjects with an arm circumference >52 cm measured at the midpoint of the length of the upper arm;
  10. History (within the last 6 months) of regular alcohol consumption exceeding 14 drinks per week for men and 7 drinks a week for women. (1 drink = 5 ounces of wine (150 mL) or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor);
  11. Treatment with thiazolidinediones (TZDs), or subcutaneously administered anti diabetic agents (eg, insulin, exenatide, liraglutide, pramlintide) within 6 weeks prior to V1;
  12. Subjects with a known hypersensitivity or intolerance to a glucagon receptor antagonist, or known prior participation in a trial involving PF 06291874;

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Podwójnie

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Komparator placebo: Placebo
Lek: Placebo
tabletka doustna
Eksperymentalny: PF-06291874, 30 mg
Lek: PF-06291874
study drug to be given as an oral tablet at 30, 60 or 100 mg
Eksperymentalny: PF-06291874, 60 mg
Lek: PF-06291874
study drug to be given as an oral tablet at 30, 60 or 100 mg
Eksperymentalny: PF-06291874, 100 mg
Lek: PF-06291874
study drug to be given as an oral tablet at 30, 60 or 100 mg

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Change From Baseline in Glycosylated Hemoglobin (HbA1c) (%) at Week 12 as Compared to Placebo
Ramy czasowe: Baseline, Week 12
HbA1c was a form of hemoglobin which was measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Baseline was defined as the last pre-dose measurement prior to first double blind dosing for the study.
Baseline, Week 12

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Change From Baseline in HbA1c (%) at Weeks 2, 4, and 8
Ramy czasowe: Baseline, Weeks 2, 4, 8
HbA1c was a form of hemoglobin which was measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Baseline was defined as the last pre-dose measurement prior to first double blind dosing for the study. n represented the available number of participants for analysis at post-baseline days.
Baseline, Weeks 2, 4, 8
Change From Baseline in Fasting Plasma Glucose at Weeks 2, 4, 8, and 12
Ramy czasowe: Baseline, Weeks 2,4,8 and 12
Fasting plasma glucose response changed from baseline at Weeks 2,4,8 and 12. Baseline was defined as the average of the measurements obtained during Day 14 visit window and Day 1 pre-dose measurement. n represented the available number of participants for analysis at post-baseline days.
Baseline, Weeks 2,4,8 and 12
Percentage of Participants Achieving Glycosylated Hemoglobin (HbA1c) <7% as Well as <6.5% at Week 12.
Ramy czasowe: Week 12
HbA1c was a form of hemoglobin which was measured primarily to identify the average plasma glucose concentration over prolonged periods of time.
Week 12
Number of Participants With Laboratory Test Abnormalities
Ramy czasowe: Baseline up to 98 days
The total number of participants with laboratory test abnormalities (without regard to baseline abnormality) was assessed. Clinical laboratory tests included hematology, chemistry, urinalysis, and some other tests.
Baseline up to 98 days
Number of Participants With Change From Baseline and Absolute Values in 12-lead Electrocardiograms (ECGs) Meeting Categorical Summarization Criteria
Ramy czasowe: Baseline up to Day 98
ECG criteria of potential clinical concern were 1), time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization (QRS interval): >=140 milliseconds (msec); >=50% increase from baseline; 2), the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization (PR interval): >=300 msec; >=25 percent (%) increase when baseline >200 msec; or increase >=50% when baseline less than or equal to (<=)200 msec; 3), time from ECG Q wave to the end of the T wave corresponding to electrical systole corrected for heart rate using Fridericia's formula (QTcF interval): absolute value >=450 - <480 msec, >=480-<500 msec, >=500 msec; increase from baseline >=30 - <60, >=60 msec.
Baseline up to Day 98
Number of Participants With Change From Baseline and Absolute Values in Vital Signs Meeting Categorical Summarization Criteria
Ramy czasowe: Baseline up to Day 98
Vital signs included seated supine systolic and diastolic blood pressure (BP) and pulse rate. Vital signs criteria of potential clinical concern were 1), BP: systolic (SBP) greater than or equal to (>=) 30 millimeters of mercury (mm Hg) change from baseline, systolic less than (<) 90 mm Hg; diastolic BP (DBP) >=20 mm Hg change from baseline, diastolic <50 mm Hg; 2), pulse rate <40 or greater than (>) 120 beats per minute (bpm).
Baseline up to Day 98
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Hypoglycemic Adverse Events (HAEs).
Ramy czasowe: Baseline up to Day 119
An adverse event (AE) was any untoward medical occurrence in a participant administered a study drug; the event need not necessarily have a causal relationship with the treatment. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reasons: death; life threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. An HAE was identified by characteristic symptoms or blood glucose levels. Any events occurring following start of treatment (defined as blinded therapy, including single blind placebo administration on Day 14) or increasing in severity were counted as treatment emergent AE.
Baseline up to Day 119
Percent Changes From Baseline for Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Weeks 2, 4, 8 and 12
Ramy czasowe: Baseline, Weeks 2, 4, 8 and 12
Fasting low density lipoprotein-cholesterol (LDL-C) percent change from baseline (defined as the mean of Day 14 and Day 1 pre-dose) at Weeks 2,4,8 and 12. n represented the available number of participants for analysis at post-baseline days.
Baseline, Weeks 2, 4, 8 and 12
Percent Changes From Baseline for Triglycerides at Weeks 2, 4, 8 and 12
Ramy czasowe: Baseline, Weeks 2, 4, 8 and 12
Triglycerides percent change from baseline (defined as the mean of Day 14 and Day 1 pre-dose) at Weeks 2,4,8 and 12. n represented the available number of participants for analysis at post-baseline days. Triglycerides MMRM was not appropriate as the data were very skewed and not normally distributed, therefore per SAP non-parametric analysis were reported, presenting medians and CIs for medians, instead. If the data had many outliers even after the log transformation the following non parametric analysis was presented instead of the MMRM. An outlier was defined as any data point falling outside of 3.5 x standard deviations the median.
Baseline, Weeks 2, 4, 8 and 12
Percent Changes From Baseline for Total Cholesterol at Weeks 2, 4, 8 and 12
Ramy czasowe: Baseline, Weeks 2, 4, 8 and 12
Total cholesterol percent change from baseline (defined as the mean of Day 14 and Day 1 pre-dose) on Weeks 2,4,8 and 12. n represented the available number of participants for analysis at post-baseline days.
Baseline, Weeks 2, 4, 8 and 12
Percent Changes From Baseline for High Density Lipoprotein-Cholesterol (HDL-C) at Weeks 2, 4, 8 and 12
Ramy czasowe: Baseline, Weeks 2, 4, 8 and 12
High density lipoprotein-cholesterol (HDL-C) percent change from baseline (defined as the mean of Day 14 and Day 1 pre-dose) at Weeks 2,4,8 and 12. n represented the available number of participants for analysis at post-baseline days.
Baseline, Weeks 2, 4, 8 and 12
Percent Changes From Baseline for Non-High Density Lipoprotein (HDL) Cholesterol at Weeks 2, 4, 8 and 12
Ramy czasowe: Baseline, Weeks 2, 4, 8 and 12
Non-HDL-C percent change from baseline (defined as the mean of Day 14 and Day 1 pre-dose) on Weeks 2,4,8 and 12. n represented the available number of participants for analysis at post-baseline days.
Baseline, Weeks 2, 4, 8 and 12
Changes From Baseline in Body Weight at Weeks 2, 4, 8, and 12.
Ramy czasowe: Baseline, Weeks 2, 4, 8 and 12
The body weight change from baseline (defined as the mean of Day 14 and Day 1 pre-dose) at Weeks 2,4,8 and 12. n represented the available number of participants for analysis at post-baseline days.
Baseline, Weeks 2, 4, 8 and 12

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Pfizer

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Przydatne linki

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów

1 października 2015

Zakończenie podstawowe (Rzeczywisty)

1 sierpnia 2016

Ukończenie studiów (Rzeczywisty)

1 sierpnia 2016

Daty rejestracji na studia

Pierwszy przesłany

17 września 2015

Pierwszy przesłany, który spełnia kryteria kontroli jakości

17 września 2015

Pierwszy wysłany (Oszacować)

18 września 2015

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

7 sierpnia 2017

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

5 lipca 2017

Ostatnia weryfikacja

1 lipca 2017

Więcej informacji

Terminy związane z tym badaniem

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • B4801010

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj